SELLAS Life Sciences Group (NASDAQ:SLS) Releases Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) issued its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03, Zacks reports. During the same period last year, the company posted ($1.34) earnings per share.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock opened at $1.20 on Friday. The stock’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $1.17. The company has a market cap of $84.46 million, a PE ratio of -1.74 and a beta of 2.43. SELLAS Life Sciences Group has a fifty-two week low of $0.77 and a fifty-two week high of $1.84.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.